RxDoctor Payments Data

Bethany Teilhet

Family · Johnson City, TNNPI 1285227231

Payments from drug & device makers

$3,897in general payments, 2019–2025

Across 190 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$707
  • AbbVie$406
  • Lilly USA, LLC$393
  • GSK$249
  • Axsome Therapeutics, Inc.$125
  • plus $789 from 18 others

What the payments were for

  • Food & beverage$3,897100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,897 in reported general payments places this provider in the 85th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$15,335
Medicare patients
31
Services billed
307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$59,818
MounjaroTirzepatide25$27,232
TrulicityDulaglutide20$21,107
EliquisApixaban30$17,545
JardianceEmpagliflozin12$14,010
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,680
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,768
LivaloPitavastatin Calcium17$6,825
Hysingla ErHydrocodone Bitartrate11$4,173
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen93$2,034
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen36$1,684
Albuterol Sulfate HfaAlbuterol Sulfate50$1,131
Omeprazole66$1,093
Fluticasone Propionate71$901
Gabapentin69$794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,227$59,81862 claims
Lilly USA, LLCMounjaro, Trulicity$393$48,33945 claims
PfizerEliquis$122$17,54530 claims
Boehringer IngelheimJardiance$27$14,01012 claims
GSKTrelegy Ellipta$249$12,68020 claims
AstraZenecaBreztri Aerosphere$707$7,76812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,706 family providers in Tennessee.

Other family in Johnson City

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →